Trending: AstraZeneca Posts 4Q Profit, Covid-19 Vaccine Sales Decline

1130 GMT - AstraZeneca PLC is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after the company posted a swing to fourth-quarter profit despite a dip in revenue which was mostly due to declining sales of its Covid-19 vaccine. The Anglo-Swedish pharma major posted net profit of $901 million compared with a loss of $347 million in the fourth quarter of 2021, when it took a hit from charges related to the acquisition of Alexion Pharmaceuticals. Profit beat analysts' expectations of $819 million. Revenue declined in the quarter to $11.21 billion from $12.01 billion in the fourth quarter of 2021, AstraZeneca said, and product sales fell to $10.80 billion from $11.50 billion the year prior. Analysts had expected revenue to be $11.25 billion in the quarter. Lower sales of Covid-19 vaccine Vaxzevria affected total sales in the fourth quarter, and the company said that revenue grew 17% when excluding the vaccine. Dow Jones & Co. owns Factiva. ( cecilia.butini@wsj.com)

(END) Dow Jones Newswires

February 09, 2023 06:46 ET (11:46 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024